Fig 4.

MK-5172 demonstrates efficacy in vivo against chronic-HCV-infected chimpanzees. (A) MK-5172 was dosed orally at 1 mg/kg b.i.d. as a suspension in Tang to chronic-HCV-infected chimpanzees harboring gt1a, gt1b, or gt1a NS3 R155K infections for 7 days. Blood samples were collected periodically, processed to plasma, and evaluated for HCV viral load. (B) A chronic-HCV-infected chimpanzee infected with a gt1b virus was dosed orally with vaniprevir or MK-5172 at 1 mg/kg b.i.d. for 7 days. The experiments were performed approximately 1.5 years apart, during which time viral load had fully rebounded.